Neurotherapeutics Group
Our group has expertise in medicinal chemistry (in association with Prana Biotechnology) and in biomarker discovery. We focus on the pathways leading to Parkinson’s disease, especially around the oxidative modifications of tau.
Research interests
|
Techniques
|
About our research
The Australian Imaging, Biomarker and Lifestyle (AIBL) Study, the Dementia Collaborative Research Centres (DCRC) and the Cooperative Research Centre for Mental Health (CRCMH) are intimately involved in our research programs, relying on patient cohorts for biomarker and imaging discovery in both neurodegenerative and psychotic illness.
Research team
Research team head
Group Head
Team members
Research and technical staff
- Xiang Liu
Selected publications
- Beauchamp LC, Liu XM, Vella LJ, Adlard PA, Bush AI, Finkelstein DI and Barnham KJ (2022), ‘ATH434 rescues pre-motor hyposmia in a mouse model of Parkinsonism’, Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 19(6):1966–1975, doi:10.1007/s13311-022-01300-0
- Beauchamp LC, Finkelstein DI, Bush AI, Evans AH and Barnham KJ (2020), Parkinsonism as a third wave of the COVID-19 pandemic?, Journal of Parkinson’s Disease, 10(4):1343–1353, doi:10.3233/jpd-202211
- McKenzie-Nickson S, Chan J, Perez K, Hung LW, Cheng L, Sedjahtera A, Gunawan L, Adlard PA, Hayne DJ, McInnes LE, Donnelly PS, Finkelstein DI, Hill AF and Barnham KJ (2018),’Modulating protein phosphatase 2a rescues disease phenotype in neurodegenerative tauopathies, ACS chemical neuroscience, 9(11):2731–2740, doi:10.1021/acschemneuro.8b00161
Contact us
For more information about our group’s research you can contact us by submitting this form.
